Sepracor inks $47M IP licensing deal with Arrow

Sepracor has struck a licensing deal with Arrow International Limited for the intellectual property rights related to stable sterile steroid suspension formulations and other applicable nebule technology for the use in developing ciclesonide, a corticosteroid. Arrow gets $250,000 on execution of the deal and payments of up to $22.5 million in support of the ciclesonide stand-alone product. In addition, Arrow gets future milestones of up to $25 million in support of Sepracor's planned ciclesonide/BROVANA combination product.

"The identification of technology to enable the successful development of a stable sterile ciclesonide suspension for nebulization has been a priority for Sepracor for our newly attained ciclesonide franchise since only a limited number of approaches can be used," said Mark H.N. Corrigan, M.D., Executive Vice President, Research and Development at Sepracor. "Arrow and its affiliates have significant experience and success in the development of inhalation solution products, particularly with corticosteroids, and we are excited to have in-licensed this technology that should assist us in moving forward two important clinical development programs in our respiratory portfolio, which could provide a significant number of patients with COPD with greater convenience in treating their disease."

- read the release

Related Articles:
AstraZeneca announces restructuring and buyout
Sepracor licenses epilepsy drug rights

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.